Blind liver biopsy: a 17-year experience

Urganci, Nafiye; Kurtaraner, Tugce; Kalyoncu, Derya; Merve Usta, Ayse; Yilmaz Ozguven, Banu.
Rev. gastroenterol. Perú ; 40(4): 322-328, oct.-dic 2020. tab
Artículo en Inglés | LILACS | ID: biblio-1280410

Documentos relacionados

  1. Blind liver biopsy: a 17-year experience.
  2. Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches.
  3. Correlation of liver fibrosis quantification by morphometry using HepaScan with the analysis of liver biopsies. A pilot study.
  4. Use of orcein as an adjunct stain in the evaluation of advanced liver fibrosis.
  5. [Histopathological evaluation of cirrhosis reversal].
  6. Hepatobiliary and Pancreatic: Liver lesions in cirrhosis: When to biopsy?
  7. Chronic liver fibrosis induction in aging causes significant ultra-structural deterioration in liver and alteration on immune response gene expressions in liver-spleen axis.
  8. Peptide-Based Nanoarchitectonics for the Treatment of Liver Fibrosis.
  9. Preoperative Liver Stiffness is Associated With Hospital Length of Stay After Cardiac Surgery.
  10. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.